Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme due for release in 2019. It is rumored that Dr Kenny De Meirleir has his eye on it as a way to break the inflammatory cascade he believes is behind CFS/ME. The drug has also been discussed on various investment forums as a potential CFS/ME treatment. It is currently undergoing clinical trials for rheumatoid arthritis and Crohn's disease. Does anyone have more information on this drug? Or have a clear understanding of how its mechanism of action might be helpful?